AZD0156: A Selective ATM Kinase Inhibitor for Cancer Research

Principle and Setup: Harnessing ATM Inhibition in Cancer Models

ATM kinase is a master regulator of DNA double-strand break (DSB) repair, checkpoint control, and genomic stability. AZD0156 (CAS 1821428-35-6) is a next-generation, orally bioavailable small-molecule inhibitor with sub-nanomolar potency and >1,000-fold selectivity against ATM over other PIKK family kinases. As a highly selective ATM kinase inhibitor for cancer research, AZD0156 enables precise modulation of DNA damage response pathways, facilitating studies in DNA repair, synthetic lethality, and metabolic adaptation.

Recent work, such as the study by Huang et al. (2023), demonstrates that ATM inhibition by agents like AZD0156 induces metabolic adaptation via macropinocytosis, revealing new avenues for therapeutic intervention and metabolic vulnerability profiling. By targeting ATM, researchers can analyze both canonical DNA DSB repair and emerging non-canonical functions, such as tumor suppressor-driven metabolic rewiring and checkpoint control modulation.

Step-by-Step Workflow: Optimizing Use of AZD0156 in Experimental Protocols

1. Compound Handling and Preparation

• Solubility and Storage: AZD0156 is supplied as a solid and demonstrates excellent solubility in DMSO (≥23.1 mg/mL with gentle warming), moderate solubility in ethanol (≥5.49 mg/mL), and is insoluble in water. For optimal stability, store the powder at -20°C, limit freeze-thaw cycles, and prepare solutions immediately before use.
• Quality Control: Each batch is accompanied by HPLC and NMR purity data (>98%), ensuring reproducibility.
• Working Solution: Dissolve AZD0156 in DMSO to create a 10 mM stock; dilute further in cell culture media immediately prior to application. Keep final DMSO concentration ≤0.1% to minimize cytotoxicity.

2. Experimental Application in Cell-Based Assays

• Cell Line Selection: Choose cancer cell lines with well-characterized DNA damage response backgrounds (e.g., wild-type or mutant p53, high c-MYC expression) to dissect context-dependent ATM functions.
• Dosing: Typical in vitro concentrations range from 10 nM to 1 µM, depending on cell sensitivity and endpoint. For combination studies (e.g., with DSB-inducing agents or macropinocytosis inhibitors), start with 100 nM AZD0156 and titrate as needed.
• Assay Endpoints:
  • γH2AX foci formation (DNA DSB marker)
  • Cell cycle checkpoint activation (phospho-CHK2, p53 stabilization)
  • Macropinocytosis quantification (FITC-dextran uptake, as demonstrated by Huang et al.)
  • Cell viability or apoptosis (MTT, Annexin V/PI staining)
  • Metabolic profiling (BCAA uptake, glucose/glutamine consumption)
• Combination Protocols: For synthetic lethality studies, co-treat with DSB-inducing agents (e.g., doxorubicin, IR) or metabolic inhibitors (e.g., EIPA for macropinocytosis blockade).

3. In Vivo Application (Preclinical Models)

• Formulation: AZD0156 can be formulated in 10% DMSO, 40% PEG 400, 5% Tween-80, and 45% saline for oral gavage.
• Dosing Regimen: Preclinical studies typically use 5–20 mg/kg, orally, daily or every other day, adjusted based on tumor model tolerability and pharmacokinetics.
• Endpoints: Tumor growth inhibition, survival analysis, pharmacodynamic biomarker assessment (ATM phosphorylation, γH2AX), and metabolic readouts (BCAA levels in tumor microenvironment).

Advanced Applications and Comparative Advantages

1. Unlocking Synthetic Lethality and Metabolic Vulnerabilities

AZD0156 uniquely enables investigation of synthetic lethality by sensitizing tumor cells to DNA-damaging agents and exploiting metabolic vulnerabilities. The article on synthetic lethality expands on how combining AZD0156 with metabolic pathway inhibitors can drive selective cancer cell death, especially in tumors with defective DNA repair or altered nutrient sensing.

For example, Huang et al. demonstrated that ATM inhibition increases macropinocytosis, providing a survival advantage under nutrient stress. However, dual inhibition of ATM and macropinocytosis robustly suppresses proliferation and induces apoptosis in vitro and in vivo, suggesting a potent, targetable vulnerability (Huang et al., 2023).

2. Comparative Insights from Recent Literature

• Precision ATM Inhibition to Unravel Metabolic and DNA Repair Vulnerabilities complements these findings by detailing experimental designs for combining AZD0156 with nutrient-deprivation or metabolic stress assays, providing actionable guidance on integrating metabolic endpoints into DNA repair research.
• The Future of Precision Cancer Research extends this perspective, highlighting how selective ATM inhibition with AZD0156 bridges the gap between canonical checkpoint modulation and metabolic rewiring, thus paving the way for next-generation, context-specific therapeutic strategies.

3. Data-Driven Performance: Selectivity and Efficacy

AZD0156 stands out with >1,000-fold selectivity for ATM over other PIKK family kinases, minimizing off-target effects and enabling precise mechanistic dissection. In preclinical combination studies, oral AZD0156 enhanced antitumor efficacy of DNA DSB-inducing agents by 1.5–3-fold compared to monotherapy, with significant tumor growth delay and improved survival in xenograft models (Transforming DNA Repair Research).

Troubleshooting and Optimization Tips

• Compound Precipitation: If precipitation occurs during stock or working solution preparation, ensure gentle warming and thorough vortexing in DMSO. Avoid aqueous dilution until the final step.
• Stability: Due to limited solution stability, prepare fresh working stocks before each experiment and avoid storage longer than 24 hours at 4°C.
• Cell Toxicity: If high background cytotoxicity is observed, verify final DMSO concentration and titrate AZD0156 to the minimal effective dose. Include vehicle controls to distinguish compound-specific effects.
• Off-Target Effects: Although AZD0156 is highly selective, confirm on-target activity by assessing ATM pathway readouts (e.g., phospho-ATM, CHK2 phosphorylation). Use isogenic or knockdown controls for specificity validation.
• Metabolic Assays: When profiling metabolic adaptation, supplement with BCAAs to dissect the dependency on macropinocytosis, as per Huang et al. This approach clarifies mechanistic links between ATM inhibition, nutrient uptake, and cell survival.
• Combination Studies: Sequence and timing of co-treatments (e.g., DSB inducers, metabolic inhibitors) are critical. Pilot time-course experiments to optimize synergy and minimize confounding toxicity.

Future Outlook: Expanding the Horizon of ATM Kinase Inhibition

The exceptional selectivity and oral bioavailability of AZD0156 position it as an indispensable reagent for cancer therapy research, enabling both basic mechanistic studies and translational investigations. The recent paradigm-shift—moving beyond canonical DNA repair roles toward metabolic adaptation and checkpoint control modulation—will continue to unlock new therapeutic strategies and biomarker opportunities.

Emerging research, such as the findings by Huang et al., highlights the importance of integrating metabolic and DNA repair endpoints. As combinations with immunotherapy, synthetic lethality partners, and metabolic inhibitors advance into early clinical evaluation, AZD0156 will remain central to unraveling the complexity of tumor cell survival and therapeutic resistance.

For protocol details, reagent specifications, and support, visit the AZD0156 product page.